Theragnostics | Diagnosis | Treatment

Targeted cancer medicine through molecular radiotherapy

Theragnostics molecularly targets and kills cancer cells whilst sparing healthy tissue. Theragnostics is cancer medicine for the 21st Century.

LEARN MORE

Targeted cancer medicine through molecular radiotherapy

Theragnostics molecularly targets and kills cancer cells whilst sparing healthy tissue. Theragnostics is cancer medicine for the 21st Century.

LEARN MORE

Play the animation to learn more about rPARPi

Play the animation to learn more about rPARPi

Latest News

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)
February 22, 2022
Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport
February 10, 2022
Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals
September 22, 2021

READ MORE NEWS

Latest News

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

February 22, 2022

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

February 10, 2022

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

September 22, 2021

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
bcookie	2 years	LinkedIn sets this cookie from LinkedIn share buttons and ad tags to recognize browser ID.
bscookie	2 years	LinkedIn sets this cookie to store performed actions on the website.
lang	session	LinkedIn sets this cookie to remember a user's language setting.
lidc	1 day	LinkedIn sets the lidc cookie to facilitate data center selection.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_ZNEJ7GCH20	2 years	This cookie is installed by Google Analytics.

Play the animation to learn more about rPARPi

Latest News

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScanTM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

Latest News

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScanTM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)